Investigating a serum for treating post-inflammatory hyperpigmentation
Safety of Serum Containing Alpha Hydroxy Acid (AHA) and Polyglutamate Acid Derivatives for Post-Inflammatory on Hyperpigmentation Skin
NA · Ungku Shahrin Medical Aesthetic Research & Innovation (USMARI) Centre · NCT05998200
This study is testing a new serum with gentle acids to see if it safely helps people in Malaysia with dark spots left from skin inflammation and if they are happy with the results.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 34 (estimated) |
| Ages | 18 Years to 40 Years |
| Sex | All |
| Sponsor | Ungku Shahrin Medical Aesthetic Research & Innovation (USMARI) Centre (industry) |
| Locations | 1 site (Petaling Jaya, Selangor) |
| Trial ID | NCT05998200 on ClinicalTrials.gov |
What this trial studies
This study evaluates the safety of a serum containing low doses of alpha hydroxy acids (1% Glycolic acid and Lactic acid) and Polyglutamate acid derivatives for individuals with post-inflammatory hyperpigmentation in Malaysia. Over an 8-week period, participants will undergo skin assessments at baseline, week 4, and week 8 to monitor safety and patient satisfaction. The study aims to determine both the safety of the serum and the satisfaction levels of the participants after using the product.
Who should consider this trial
Good fit: Ideal candidates are Malaysian individuals aged 18 to 40 with post-inflammatory hyperpigmentation.
Not a fit: Patients with known systemic or skin diseases, pregnant or breastfeeding women, and those with a history of certain dermatologic conditions or cosmetic procedures may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a safe and effective treatment option for individuals suffering from post-inflammatory hyperpigmentation.
How similar studies have performed: While similar studies have explored the use of AHAs for skin conditions, the specific combination and focus on safety in this context may be novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Malaysian from 18 to 40 years old. * Participants with post-inflammatory hyperpigmentation (PIH). Exclusion Criteria: * Participant with known systemic or skin disease and any underlying medical illness * Pregnant, breastfeeding women or planned pregnancy during the study period. * Had reported history of dermatologic conditions (i.e. Atopic dermatitis, psoriasis) or known allergies to any ingredients that may be found in the product. * Had any cosmetic procedures such as Botox, laser and light treatment, facial surgery, chemical peel and any procedures that may improve skin texture 1 month before the study. * Had history of taking isotretinoin for the past 6 or 12 month and AHA (alpha hydroxyl acids) containing products or any other products for treating hyperpigmentation skin or melasma 1 month prior to study.
Where this trial is running
Petaling Jaya, Selangor
- Ungku Shahrin Medical Aesthetic Research & Innovation (USMARI) Centre — Petaling Jaya, Selangor, Malaysia (RECRUITING)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Healthy, Aesthetic, Cosmetic, Post-inflammatory hyperpigmentation